Salmeterol
Active pharmaceutical substance formulated in Jan Aushadhi generic products for Respiratory & Allergy treatment.
🧴 Clinical Application
Administer twice daily (morning and evening, approximately 12 hours apart) by oral inhalation. MDI: Shake well, inhale slowly and deeply, and hold breath for 10 seconds. Rotacaps: Inhale dry powder deeply through the specialized rotahaler device. MANDATORY: Rinse mouth with water and spit out immediately after inhalation. NOT for acute bronchospasm rescue (has slow bronchodilator onset ~10-20 minutes).
⚠️ Side Effects
Common: Oropharyngeal candidiasis, hoarseness/dysphonia, throat irritation, headache, palpitations, muscle cramps. Rare/Severe: Paradoxical bronchospasm, pneumonia in COPD patients, adrenal suppression with prolonged high doses, and bone density reduction.
🛡️ Safety Warnings
Black Box Warning: Not for acute asthma attacks; patients must carry a rapid-acting rescue inhaler (salbutamol). Rinse mouth and gargle with water after every inhalation. LABA monotherapy is contraindicated in asthma (must always be paired with an inhaled steroid).
Jan Aushadhi Products containing Salmeterol
Found 4 generic formulation(s) containing this active ingredient.
Salmeterol 50mcg + Fluticasone 250mcg Rotacaps
Salmeterol Xinafoate (25mcg/50mcg) and Fluticasone Propionate (100mcg/250mcg/500mcg Inhaler, Rotacaps) is a benchmark inhaled corticosteroid and long-acting beta-2 agonist combination on the WHO Model List of Essential Medicines. Fluticasone exerts profound local anti-inflammatory, immunosuppressive, and anti-edematous effects in bronchial mucosa with low systemic bioavailability due to extensive first-pass metabolism. Salmeterol provides long-acting bronchodilation lasting over 12 hours via persistent beta-2 receptor activation. Indicated for maintenance therapy of persistent bronchial asthma and maintenance treatment of airflow obstruction in patients with severe COPD and recurrent exacerbations.
Salmeterol 25mcg + Fluticasone Propionate 250mcg Inhaler
Salmeterol Xinafoate (25mcg/50mcg) and Fluticasone Propionate (100mcg/250mcg/500mcg Inhaler, Rotacaps) is a benchmark inhaled corticosteroid and long-acting beta-2 agonist combination on the WHO Model List of Essential Medicines. Fluticasone exerts profound local anti-inflammatory, immunosuppressive, and anti-edematous effects in bronchial mucosa with low systemic bioavailability due to extensive first-pass metabolism. Salmeterol provides long-acting bronchodilation lasting over 12 hours via persistent beta-2 receptor activation. Indicated for maintenance therapy of persistent bronchial asthma and maintenance treatment of airflow obstruction in patients with severe COPD and recurrent exacerbations.
Salmeterol 50mcg + Fluticasone Propionate 100mcg Powder for Inhalation
Salmeterol Xinafoate (25mcg/50mcg) and Fluticasone Propionate (100mcg/250mcg/500mcg Inhaler, Rotacaps) is a benchmark inhaled corticosteroid and long-acting beta-2 agonist combination on the WHO Model List of Essential Medicines. Fluticasone exerts profound local anti-inflammatory, immunosuppressive, and anti-edematous effects in bronchial mucosa with low systemic bioavailability due to extensive first-pass metabolism. Salmeterol provides long-acting bronchodilation lasting over 12 hours via persistent beta-2 receptor activation. Indicated for maintenance therapy of persistent bronchial asthma and maintenance treatment of airflow obstruction in patients with severe COPD and recurrent exacerbations.
Salmeterol 50mcg + Fluticasone 500mcg Rotacaps
Salmeterol Xinafoate (25mcg/50mcg) and Fluticasone Propionate (100mcg/250mcg/500mcg Inhaler, Rotacaps) is a benchmark inhaled corticosteroid and long-acting beta-2 agonist combination on the WHO Model List of Essential Medicines. Fluticasone exerts profound local anti-inflammatory, immunosuppressive, and anti-edematous effects in bronchial mucosa with low systemic bioavailability due to extensive first-pass metabolism. Salmeterol provides long-acting bronchodilation lasting over 12 hours via persistent beta-2 receptor activation. Indicated for maintenance therapy of persistent bronchial asthma and maintenance treatment of airflow obstruction in patients with severe COPD and recurrent exacerbations.
Brand Equivalents & Price Comparison
Compare Jan Aushadhi generic prices against popular commercial brands for Salmeterol.
| Generic Formulation | Pack Size | Jan Aushadhi Price | Commercial Brand Equivalents | Avg. Commercial Price | Savings |
|---|---|---|---|---|---|
| Salmeterol 50mcg + Fluticasone 250mcg Rotacaps | 30's | ₹112.50 | SEROFLO, AIRFLOW, MAXIFLO | ₹431.87 | 74% Save |
| Salmeterol 25mcg + Fluticasone Propionate 250mcg Inhaler | 100 MD | ₹234.38 | SEROFLO | ₹1716.13 | 86% Save |
| Salmeterol 50mcg + Fluticasone Propionate 100mcg Powder for Inhalation | 30's | ₹70.31 | SEROFLO | ₹465.12 | 85% Save |
| Salmeterol 50mcg + Fluticasone 500mcg Rotacaps | 30's in Monocarton | ₹140.63 | SEROFLO | ₹465.12 | 70% Save |
Frequently Asked Questions (FAQ)
Get answers to common queries about Salmeterol generics.